Sponsored byOpenSourceMed— Open-source medical research & education
Association with Symptoms
Summaries of cohort studies examining whether persistent spike protein detection correlates with multi-system symptoms — including findings of association in subsets and null results in others.
Swank & Walt — Circulating spike associated with Long COVID after infection
Evidence: Medium
Plasma from people with post-acute sequelae of COVID-19 (PASC) and from people recovering from COVID-19 without sequelae was tested with an ultra-sensitive Simoa assay. SARS-CoV-2 spike was detected predominantly in PASC patients, up to 12 months after diagnosis. This is an infection study; it did not examine vaccination.
Limitations
Observational design; no randomized controls
Small cohort from a single research network
Assay sensitivity limits detection in low-level carriers
Association does not establish that spike causes symptoms
Yale LISTEN — Circulating spike in post-vaccination syndrome
Evidence: Low
A cross-sectional preprint of 42 people with post-vaccination syndrome (PVS) and 22 healthy controls found higher circulating spike protein in the PVS group, along with differences in T-cell profiles and more frequent signs of Epstein-Barr virus reactivation.
Limitations
Preprint; not yet peer reviewed
Small, self-selected symptomatic cohort
Unrecognised infection cannot be fully excluded as the spike source
Rong et al. — Spike at the skull-meninges-brain axis after infection
Evidence: Low
Using optical tissue clearing and imaging, researchers found SARS-CoV-2 spike protein accumulated in the skull marrow, meninges and brain of deceased COVID-19 patients, persisting long after viral clearance. Long COVID patients had raised markers of neurodegeneration in cerebrospinal fluid, and spike injection alone caused neuroinflammation in mice.
Limitations
Autopsy findings; persistence duration not quantified
Infection-derived spike; not a vaccine study
Human-to-symptom link inferred partly from mouse models
Several population-based and controlled studies have not found a consistent association between circulating spike detection and symptom burden in general vaccinated populations. Detection rates in asymptomatic individuals and the role of assay false positives/false negatives remain active areas of investigation.
Multi-system symptom patterns in persistent-carrier cohorts
Evidence: Low
In subsets of patients with prolonged spike detection, reports include overlapping cardiovascular, neurological, and autonomic symptoms reminiscent of post-acute infection syndromes. Whether this reflects shared immunological pathways, endothelial dysfunction, or reporting bias is not yet resolved.
Limitations
Overlap with long COVID symptom profiles confounds attribution
No validated clinical biomarker threshold for treatment decisions
Psychosocial and functional factors not fully accounted for
Serum spike persistence not associated with ME/CFS diagnosis
Evidence: Medium
A study measuring serum spike protein in post-COVID patients with predominant fatigue and exertional intolerance — including a subset meeting ME/CFS diagnostic criteria — found no association between spike persistence and ME/CFS status. This is a notable null finding given fatigue is one of the most commonly proposed spike-associated symptoms.
Limitations
Single-cohort study; may not generalize to other post-COVID fatigue phenotypes
ME/CFS diagnostic criteria are themselves symptom-based and heterogeneous
Absence of correlation does not rule out a role for spike in a minority subgroup
Spike protein as one of several biomarkers in long COVID risk stratification
Evidence: Medium
A broader biomarker-based risk assessment approach situates spike protein persistence alongside proinflammatory mediators (cytokines, complement markers) as part of a multi-marker strategy for anticipating postinfection sequelae, rather than treating spike detection as a standalone diagnostic signal.
Limitations
Proposed risk-assessment framework, not a validated clinical diagnostic test
Relative weighting of spike vs. other biomarkers not firmly established
Requires prospective validation across diverse patient populations
Retrospective comparison of spike variants and long COVID biological factors
Evidence: Low
A retrospective cohort study comparing biological factors across SARS-CoV-2 spike protein variants examined associations with long COVID outcomes, contributing variant-stratified evidence to the broader symptom-correlation literature rather than treating spike protein as a single uniform exposure.
Limitations
Retrospective design; residual confounding by variant-era clinical practice differences
Regional cohort (Thailand); generalizability to other populations unclear
Variant classification relied on epidemiological timing rather than individual sequencing in all cases
Narrative review of spike protein in long COVID pathophysiology
Evidence: Low
A 2025 review synthesizes proposed pathophysiological mechanisms linking spike protein (viral or vaccine-derived) to Long COVID symptom clusters, integrating the mechanistic literature (endothelial, neurologic, immune) with the clinical symptom-correlation studies summarized on this page.
Limitations
Narrative rather than systematic review methodology
Synthesizes mechanistic plausibility rather than new primary clinical data
Causal role of spike persistence in symptom generation remains unproven
The relationship between spike persistence and symptoms remains contested. Some symptomatic cohorts show higher detection rates, but population-level studies often fail to replicate a strong correlation. Causality has not been established in any prospective trial.